|
| |
acapodene gtx Pages on BioPortfolio:
BioPortfolio - GTX
GTx has licensed to Ipsen Group exclusive rights in Europe to develop and commercialize ACAPODENE®. GTx also is developing ostarine, a first-in-class ...
http://www.bioportfolio.com/biocorporate/32439-GTX.html...
|
BioPortfolio - gtx pharma
11 Nov 2008 ... On September 2006, GTx, Inc. granted the Group an exclusive licence to develop and market Acapodene®, a Selective Estrogen Receptor ...
http://www.bioportfolio.com/search/gtx_pharma.html...
|
BioPortfolio - GTx, Inc.
GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first,
...
http://www.bioportfolio.com/biocorporate/23753-GTx,_Inc..htm...
|
La Merie R&D Pipeline News Therapeutic Edition Sample
Acapodene® toremifene citrate. Slective estrogen receptor modulation. Small molecule. GTx. Small molecule. High grade prostatic intraepithelial neoplasia
...
http://www.bioportfolio.com/promote/Therapeutic%20Edition%20...
|
Results from other life science and pharmaceutical sites:
Merck News Item
6 Nov 2007 ... GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE. GTx has agreed to a collaboration with ...
http://www.merck.com/newsroom/press_releases/research_and_de...
|
BioPortfolio - GTX
GTx has licensed to Ipsen Group exclusive rights in Europe to develop and commercialize ACAPODENE®. GTx also is developing ostarine, a first-in-class ...
http://www.bioportfolio.com/biocorporate/32439-GTX.html...
|
GTx, Inc. Announces Initiation of Phase IIIb Extension Trial Of ...
GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first,
...
http://www.biospace.com/news_story.aspx?NewsEntityId=16008...
|
Selective estrogen receptor modulators for the che...[Urology ...
Selective estrogen receptor modulators (SERMs) have shown the ability to prevent (GTx-006 [acapodene]) and treat (GTx-006 and arzoxifene) prostate cancer, ...
http://www.ncbi.nlm.nih.gov/pubmed/11295598...
|
BioWorld Today
7 Nov 2007 ... GTx's lead SERM product Acapodene (toremifene citrate) is being tested to treat serious adverse effects related to androgen deprivation ...
http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher...
|
{1} Acquires Exclusive Rights In The U.S. For Toremifene In All ...
Toremifene is the active component in ACAPODENE(TM) (Toremifene Citrate), a product candidate that GTx is developing in late-stage clinical trials for two
...
http://www.biospace.com/news_story.aspx?NewsEntityId=1843262...
|
Full year 2006 results
19 Mar 2007 ... Partnership with GTx Inc for Acapodene in Europe. Partnership with Tercica for. Increlex in Europe. Strategic Priorities ...
http://www.ipsen.com/articles/investorrelations/financialres...
|
Prostate Cancer and Prostatic Diseases - Contemporary clinical ...
Pre-clinical studies have demonstrated that at low doses, toremifene (Acapodene, Gtx Inc, Memphis, TN, USA) selectively inhibits ER- alpha ...
http://www.nature.com/pcan/journal/v11/n1/full/4501014a.html...
|
Ipsen, an innovation driven international specialty pharmaceutical ...
The Group has acquired the rights from the US Biotech company GTx, specialised in men's health, for the development and marketing of Acapodene® for all ...
http://www.ipsen.com/?page=researchdevelopment&content=proje...
|
Handful Of Biotechs Could Defy Meltdown: Financial News - Yahoo ...
GTX has positive phase three trial data in hand for its lead drug, Acapodene, and a late-stage pipeline that most people have overlooked, Sendek says. ...
http://biz.yahoo.com/ibd/081024/health.html?.v=1...
|
|
